- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07651345
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore (REMIND1)
Randomized Controlled Trials to Evaluate Outreach Strategies for Increasing Mammogram Uptake in Singaporean Women Who Are Defaulted Repeat Screeners
Breast cancer is the most common cancer among women in Singapore, accounting for nearly 30% of all female cancers. While regular biennial mammography can reduce mortality, screening rates in Singapore remain low at 34.7%; well below the 70% threshold required for population-level impact. Despite a national screening program in place since 2002, uptake continues to be hindered by psychological, cultural, and logistical barriers. Although various studies have explored different behavioural interventions to boost mammogram uptake; ranging from reminders (traditional mailers, phone calls, text messages) and education to financial incentives, their effectiveness varies by population and context. Furthermore, few large-scale, prospective studies have been conducted locally. Prior research in Singapore is either outdated or limited in scope, and there is a particular lack of rigorous trials evaluating behavioral interventions tailored to women who have defaulted on screening, who faces distinct psychological and behavioral barriers; ranging from low perceived risk and fear, to false reassurance from prior normal results or lack of reminders, or had bad experience (procedural pain or prior false positive results) during last mammogram. Engaging these women is critical, yet challenging, and failure to do so undermines efforts to achieve broad population coverage.
The REMIND Study addresses this critical gap by evaluating five pragmatic and scalable outreach strategies to increase mammogram uptake among women who had their last screening more than 2 years ago and are currently overdue. Through a large, randomized controlled trial, the study will generate much-needed local evidence on what works to reengage these women. Findings will directly inform national screening policies and the design of future outreach efforts tailored to Singapore's diverse population.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The REMIND Study is a five-arm randomized controlled trial (RCT) designed to evaluate the effectiveness of a few behavioral interventions to increase mammogram uptake among women aged 50-69 years who have defaulted on mammogram screening. The study's specific aim is to identify effective, affordable, and scalable behavioral interventions that can be implemented in Singapore's general population to improve participation in surveillance mammography. This is a minimal-risk, population-based study that does not require participant visits or in-person interaction, except for a subset involved in a follow-up telephone survey.
Eligibility Criteria: Singaporean women, aged 50-69, who are eligible for free biennial mammograms, with no history of prior breast cancer, have had at least one mammogram before, but not screened in the past 2 years will be will be identified using the NUH electronic medical health records system (EPIC). We will restrict the selection to NUHS patients who are registered users of the NUHS App. To further select/narrow down the eligible participants app activity or last log in date will be used. Patients who signed up the NUHS App have all consented to receive push notifications on research studies. There are over 600,000 registered users of NUHS App. The required 12,750 patients for the study will be randomly selected from these eligible patients.
Randomization and Intervention Arms: A total of 12,750 eligible women will be randomly assigned in equal proportions (n=2,550 per arm) to one of the following five groups:
- no intervention (control);
- standard mailed reminder (MR);
- MR plus a second MR sent four weeks later;
- MR with a pre-scheduled mammogram appointment; and
- MR containing behavioral nudge messaging (e.g., social norm or gain or loss framing techniques).
Randomization will be computer-generated. NOTE: Arm 1 represents the current standard practice at NUHS, where patients are not routinely invited or reminded to attend mammogram screenings.
Women in intervention arms 2-5 will receive their respective outreach materials by post (personalized mailers on NCIS letter head) as well as push notifications via the NUHS app. 5-7 days after the mailers are sent, 1st batch of PN will be sent. Up to three batches of PN will be sent to all participants in Arms 2-5, 3 weeks apart. The push notifications will either be linked to a microcontent landing page or a webpage on NCIS website. The content of the mailers and landing page/ webpage will be the same explaining the importance of regular mammography, tailored messages according to each intervention type, and relevant booking instructions or appointment details. These materials have been designed to reflect evidence-based behavioral science strategies and were co-developed in consultation with clinicians, behavioural science experts, and community stakeholders. Participants in the control arm (Arm 1) will not receive any intervention.
This is a minimal-risk study. There are no in-person visits, clinical procedures, or additional tests required. Participation primarily involves receiving reminders. Women may choose to opt out of the study at any time.
Outcome measurement: All data on mammogram completion will be obtained from existing sources such as electronic medical records and the national screening registry. The primary outcome is mammogram uptake within four months of the first intervention (date of sending the mailer/ push notification, which ever is later). In addition to the primary time point, mammogram uptake data may also be extracted at the 6-month and 12-month marks following the intervention. These extended follow-up points will allow for the assessment of any delayed uptake, which may help to understand the longer-term impact of the interventions. No new clinical data will be generated from participants.
NOTE: To avoid a huge surge in calls to the appointment booking hotline number, mailers will be sent in a staggered manner over 4-12 weeks. Hence, the collection of mammogram completion data will also be staggered and will be 4 months from the day of sending the mailers/PNs which ever is the later. Similarly, for the participants in Arm 4 (mailer reminder with pre-scheduled appointment), the mailers/PN will be sent out 4-6 weeks prior to the appointment date and the mammogram completion date will be calculated four months from the date the mailer/PN was sent.
Post-trial telephone survey: In addition post-trial, a subset of participants from Arms 2-5, will be randomly selected to participate in a telephone survey aimed at understanding motivations, barriers, and perceptions related to the interventions and screening. Participants will be randomly selected and contacted until a total of up to 70 participants in each arm responds and takes part in the survey. About 3-8 weeks post trial, the participants will be contacted via phone, and verbal consent will be obtained prior to initiating the survey. They will be informed that the survey will take about 5-10 minutes, their participation is voluntary, they may skip any question or withdraw at any time, and their responses will remain confidential. Trained research staff will be performing the telephone survey.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Singapore, Singapur
- National University Hospital Singapore
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Singaporean citizen
- Age 50-69
- Registered as a patient at the National University Hospital
- Registered and active user of NUHS App
- Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network
- Must be defaulted repeat screeners : Must have done one prior mammogram screening but not in the past 2 years
Exclusion Criteria:
- Diagnosis of breast cancer in EPIC
- Mammogram done in the past 24 months in EPIC
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm 5: Postalische Erinnerung mit erweiterten Nachrichten
Erhält postalische Erinnerung mit verbesserter Nachrichtengestaltung
|
Receives one mailed reminder with enhanced messaging motivating recipient to undergo screening
|
|
Kein Eingriff: Control Arm (Arm 1)
Does not receive any reminder to go for mammogram
|
|
|
Experimental: Arm 2: One mailed reminder
Receives a single mail reminder
|
Erhält eine postalische Erinnerung mit grundlegenden Informationen zu Brustkrebs und Anweisungen zur Terminvereinbarung für eine Mammographie
|
|
Experimental: Arm 3: Two mailed reminders
Receives two mail reminders, 4 weeks apart
|
Receives a mailed reminder + follow-up mailed reminder, 4 weeks after the first
|
|
Experimental: Arm 4: Mailed Reminder with Prescheduled Appointment
Receives a mailed reminder with prescheduled appointment
|
Erhält eine postalische Erinnerung mit einem vorgeplanten Termin und Anweisungen zur Terminänderung
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Comparison of proportion of participants completing surveillance mammography within 4 months after intervention assignment between interventional arms (2-5) and control arm (Arm 1)
Zeitfenster: 4 months from the time participants receive the intervention/reminder
|
The proportion of women who undergo surveillance mammography within 4 months of receiving the study intervention/reminder will be compared between Arm 1 (control) and Arms 2-5.
Mammogram completion will be confirmed through electronic medical records.
Results will be reported as the percentage of participants completing mammography in each study arm.
Unit of Measure: Percentage of participants (%)
|
4 months from the time participants receive the intervention/reminder
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mammographie-Teilnahme 6 und 12 Monate nach Studienende
Zeitfenster: 6 und 12 Monate nachdem die Teilnehmer die erste postalische Erinnerung erhalten haben
|
Vergleich der Mammographieabschlüsse 6 und 12 Monate nach der ersten Studie
|
6 und 12 Monate nachdem die Teilnehmer die erste postalische Erinnerung erhalten haben
|
|
Association between participant characteristics and completion of surveillance mammography within 4 months
Zeitfenster: 4 months from the time participants receive the intervention/reminder
|
Multivariable logistic regression will be used to evaluate the association between participant characteristics and mammogram completion within 4 months after intervention.
Covariates include age, race, housing type, and duration overdue for screening.
Results will be reported as adjusted odds ratios with 95% confidence intervals.
|
4 months from the time participants receive the intervention/reminder
|
|
Post-trial telephone survey
Zeitfenster: 1-2 months post-trial
|
A post-trial telephone survey of about 280 participants will gather insights into their response to the interventions.
The study aims to provide actionable insights into effective, scalable interventions to improve mammography uptake and reduce breast cancer mortality in Singapore.
|
1-2 months post-trial
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2025-0790
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Xijing HospitalAktiv, nicht rekrutierendBrustkrebs | Brustkrebs (Triple Negative Breast Cancer (TNBC))China
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
Shanghai Henlius BiotechNoch keine RekrutierungBrustkrebs (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi SankyoRekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
Jessica Mezzanotte SharpeRekrutierungNicht-kleinzelligem Lungenkrebs | Klassisches Hodgkin-Lymphom | Plattenepithelkarzinom Mund | Melanom (Hautkrebs) | Brustkrebs (Triple Negative Breast Cancer (TNBC)) | Invasives Mammakarzinom | Nierenzellkarzinom (Nierenkrebs) | MSI-H/dMMR RektumkarzinomVereinigte Staaten
Klinische Studien zur Arm 2: Eine postalische Erinnerung
-
Universiti Putra MalaysiaUnited NationsNoch keine RekrutierungSarkopenie | Kognitive Gebrechlichkeit | ErnährungsinterventionenMalaysia
-
VA Office of Research and DevelopmentAbgeschlossenVerletzungen des RückenmarksVereinigte Staaten
-
Jonsson Comprehensive Cancer CenterAmerican Cancer Society, Inc.AbgeschlossenDarmkrebsVereinigte Staaten
-
Hôpital NOVOAbgeschlossenHemiplegie und/oder Hemiparese nach SchlaganfallFrankreich
-
Abbott NutritionAbgeschlossenMagen-Darm-ToleranzVereinigte Staaten
-
University of PennsylvaniaAbgeschlossenHIV-1-InfektionenVereinigte Staaten
-
Ohio State UniversityNational Institute on Drug Abuse (NIDA)AbgeschlossenHypothetischer CannabiskaufVereinigte Staaten
-
AmgenAbgeschlossenLeukämie | Myeloische Leukämie | Krebs | Hämatologische MalignomeVereinigte Staaten
-
The University of Texas Health Science Center,...Brighter BitesAbgeschlossen
-
Children's Cancer Hospital Egypt 57357Abgeschlossen